Use the Pediatric Dosing Calculator for fast, accurate dosing
COVID-19
Resources


Lantheus Addresses COVID-19
We remain grateful for the work all health care workers and government officials are doing to keep our communities healthy and safe. We send our thoughts and prayers to those affected by COVID-19 and will continue to do our part to keep our teams and our communities safe and to support our customers and the patients they serve.
62%
Echoes with DEFINITY® were acquired 62% faster than unenhanced echoes1
Lantheus Archived Webinar
COVID-19: Clinical Experience with DEFINITY® from
the Front Line in NYC
A question and answer session with Dr. Martin Goldman, Dr. Lori Croft, and Samantha Buckley, RDCS of Mount Sinai Hospital in New York City. They share their experience treating patients and provide insight into the use of DEFINITY® during the COVID-19 pandemic.
Medical Society Resources
American Society of Echocardiography Coronavirus (COVID-19) Resources
American College of Cardiology COVID-19 Hub
References:
-
Sperling D, Lai AC, Bienstock SW, et al. Echocardiography in the time of Covid-19: ultrasound enhancing agents save time and augment diagnostic information. Int J Cardiol. 2022;346:100-102. doi:10.1016/j.ijcard.2021.11.040
INDICATION
DEFINITY® is indicated, after activation, for use in adult and pediatric patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
IMPORTANT SAFETY INFORMATION
BOXED WARNING: SERIOUS CARDIOPULMONARY REACTIONS
Serious cardiopulmonary reactions, including fatalities, have occurred uncommonly during or following perflutren-containing microsphere administration. Most serious reactions occur within 30 minutes of administration.
- Assess all patients for the presence of any condition that precludes DEFINITY® administration.
- Always have resuscitation equipment and trained personnel readily available.
DEFINITY® Customer Service 1.800.299.3431

TOP